As the government launches its Industrial Strategy white paper, the Association of the British Pharmaceutical Industry (ABPI) – the trade group for the pharmaceutical industry in the UK – have welcomed the government's roadmap for business.
In response to the BMJ investigation into bevacizumab (Avastin) as a treatment for wet age-related macular degeneration (AMD), Dr Sheuli Porkess, ABPI's Head of Medical Affairs and Clinical Research said:
The Association of the British Pharmaceutical Industry (ABPI) has responded to a Cochrane Collaboration publication, which has assessed all the drug company trials of the breakthrough hepatitis C treatments.
Following the news that a new breast cancer medicine -Palbociclib - from Pfizer has been ruled too expensive to justify its use on the NHS by the National Institute for Health and Care Excellence (NICE), ABPI's Commercial Director, Dr Richard Torbett said it was time to review the way in which...
Following today’s [26 July] announcement that Steve Oldfield will take up the role of Chief Commercial Officer at the Department of Health this October, the Association of the British Pharmaceutical Industry has issued the following statement.
The Association of the British Pharmaceutical Industry (ABPI) has admitted the American biotech bluebird bio, Inc. as a full member, effective Thursday 20 July 2017.
The Association of the British Pharmaceutical Industry (ABPI) has responded to an in-depth investigation reported in The Times today (Friday 3 June), which reported price increases in out of patent medicines.
60% of major pharmaceutical companies have increased investment in outsourced and collaborative drug discovery work in the UK over the last 10 years, whilst simultaneously decreasing the number of in-house drug discovery lab staff, according to a new report published today by the Association of the...
Taskforce calls on Government to make the UK the go to destination for international investment in ground-breaking medicinal therapies.
Following yesterday's announcement by the Department of Health of a new £816 million investment in health research, the Association of the British Pharmaceutical Industry (ABPI) have welcomed the record amount as a signal of Government's commitment to invest in innovation.